戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 T by up to 400% (P<0.001 versus baseline and procainamide).
2  shortening of cycle length were enhanced by procainamide.
3 similar to that caused by cells treated with procainamide.
4 AHA with the DNA methyltransferase inhibitor procainamide.
5 provocative drug testing with epinephrine or procainamide.
6 nd in T cells treated with 5-azacytidine and procainamide.
7 ngth (CL) less (16% versus 26%, P<.001) than procainamide.
8 nsion was the major adverse effect seen with procainamide.
9 soproterenol infusion, and after intravenous procainamide.
10  VF were 345 ms at baseline and 380 ms after procainamide.
11 he effect of intravenous ajmaline (1 mg/kg), procainamide (10 mg/kg), or flecainide (2 mg/kg) on the
12 d administration of verapamil (17 patients), procainamide (10 patients), or saline (20 patients).
13 ody weight per min) shortened (p < 0.05) and procainamide (15 mg/kg, then 2 mg/min) prolonged (p < 0.
14  to 200 Hz at baseline and after addition of procainamide (20 micromol/L) or propafenone (1 micromol/
15 had a significantly higher success rate than procainamide (51% [22 of 43] vs. 21% [8 of 38], p=0.005)
16 had a significantly higher success rate than procainamide (76% [13 of 17] vs. 14% [3 of 22], p=0.001)
17                 We report here that the drug procainamide, a nonnucleoside inhibitor of DNA methyltra
18 seline and 4.45+/-1.80 s(-1) x cm(-2) during procainamide administration (P<.001).
19 e up more frequently at baseline than during procainamide administration.
20 ar tachyarrhythmias refractory to lidocaine, procainamide and bretylium were randomized to receive on
21  with a 70% decrease in VF inducibility with procainamide and elimination of VF with propafenone.
22                                              Procainamide and hydralazine are drugs that cause lupus
23 pigenetic DNA modification, is implicated in procainamide and hydralazine induced lupus, as well as i
24 expressed on CD4(+) lupus T cells as well as procainamide and hydralazine treated T cells, and contri
25 th Dnmt and ERK pathway inhibitors including procainamide and hydralazine.
26 tages, only correction of fever and combined procainamide and hypothermia appeared to be efficacious.
27 procainamide or hypothermia; and 7) combined procainamide and hypothermia.
28 oducts including pharmaceuticals benzocaine, procainamide and mesalazine, and 4-aminophenol - precurs
29                A side effect of therapy with procainamide and numerous other medications is a lupus-l
30                     Long-term treatment with procainamide and numerous other medications is occasiona
31                  During steady-state pacing, procainamide and propafenone prolonged APD90 by 12% and
32 hyltransferase inhibitors (5-azacytidine and procainamide) and 3 ERK pathway inhibitors known to decr
33 h as chloroquine, haloperidol, erythromycin, procainamide, and ofloxacin known to activate T2Rs.
34  The conversion rates in AFL with ibutilide, procainamide, and placebo were 64% (29 of 45 patients),
35                  Seven patients who received procainamide became hypotensive.
36       In TG(N488I) mice with pre-excitation, procainamide blocked bypass tract conduction, whereas ad
37  Wavelength was not changed significantly by procainamide but was shortened fourfold by propafenone a
38                                              Procainamide decreases the number of wavelets during VF
39  procainamide-hydroxylamine, a metabolite of procainamide, develop autoimmune features resembling dru
40 trial flutter has a fully excitable gap, and procainamide does not convert the gap from full to parti
41 educe the slope of the restitution relation (procainamide) does not prevent the induction of VF, nor
42 n (APD) during VF and that its prevention by procainamide eliminates spontaneous wave break.
43 f the specificity of procainamide for DNMT1, procainamide failed to lower genomic 5-methyl-2'-deoxycy
44 he first time, we present the combination of procainamide fluorescent labeling with sialic acid linka
45  the efficacy and safety of ibutilide versus procainamide for conversion of recent-onset atrial flutt
46    As further evidence of the specificity of procainamide for DNMT1, procainamide failed to lower gen
47                           All animals in the procainamide group developed either second-degree or com
48  group compared with 11 (18.3%) of 60 in the procainamide group had successful termination within 1.5
49 t shortening of the first post-AF ERP in the procainamide group.
50 tic peak corresponding to [GlcNAc + Fucose + Procainamide + H](+) in the tandem MS data of fucosylate
51                                              Procainamide has been shown to inhibit DNA methyltransfe
52 ally when other agents such as lidocaine and procainamide have not been effective.
53                                Specifically, procainamide HCl is loaded into the pores of bio-MOF-1 u
54                         T cells treated with procainamide, hydralazine, and other Dnmt and ERK pathwa
55                Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell D
56 ore the influence of labeling N-glycans with procainamide hydrochloride to inhibit fucose migration d
57  successive 10-min IV infusions of 400 mg of procainamide hydrochloride.
58                Two intrathymic injections of procainamide-hydroxylamine (PAHA), a reactive metabolite
59                Two intrathymic injections of procainamide-hydroxylamine (PAHA), a reactive metabolite
60 ggest that prevention of anergy induction by procainamide-hydroxylamine may also take place in vivo d
61             Mice injected in the thymus with procainamide-hydroxylamine, a metabolite of procainamide
62 anergy induction required 2 h of exposure to procainamide-hydroxylamine, and this state remained for
63                                  Addition of procainamide-hydroxylamine, but not procainamide or its
64 ndergo positive selection in the presence of procainamide-hydroxylamine, they fail to establish unres
65 1 Brugada pattern was induced by intravenous procainamide in 3 of 4.
66 nversion efficacy of ibutilide compared with procainamide in AFL is correlated with a relatively grea
67 y, with emphasis on combined hypothermia and procainamide in difficult cases, appears to be an effect
68 effects of ibutilide with the class IA agent procainamide in humans during AFL and AF.
69                         In AF, ibutilide and procainamide induced similar increases in atrial CL (48%
70 ted in patients with a standard or high-lead procainamide-induced Brugada pattern (without previous c
71 The safety, yield, and prognosis of a type 1 procainamide-induced Brugada pattern are incompletely un
72                       In 137 patients with a procainamide-induced type 1 Brugada pattern (with no pre
73                Patients with an asymptomatic procainamide-induced type 1 Brugada pattern are at very
74 ation were registered at baseline and during procainamide infusion (serum concentration, 9.3+/-1.9 mi
75                                The safety of procainamide infusion and yield of a type 1 Brugada patt
76                      In an additional 6 RVs, procainamide infusion converted VF to VT.
77       In 947 consecutive patients undergoing procainamide infusion for the diagnosis or exclusion of
78                                              Procainamide infusion is extremely safe for the diagnosi
79 ms, and 51+/-16 mm, respectively, and during procainamide infusion, values became 125+/-11 ms (P<.001
80 seline and in 6 of the 100 runs of VF during procainamide infusion.
81                                              Procainamide infusions did not identify additional affec
82 droxylamine (PAHA), a reactive metabolite of procainamide, into (C57BL/6 x DBA/2)F1 mice resulted in
83                                              Procainamide is a competitive DNA methyltransferase (Dnm
84                                              Procainamide is commonly used for conversion of recent-o
85                   Therapeutic treatment with procainamide is occasionally associated with the develop
86 e, we present a workflow for the analysis of procainamide-labeled GSL glycans using HILIC-IM-MS and a
87 pamil, but not the sodium channel antagonist procainamide, markedly attenuates acute, AF-induced chan
88 th epigenetic alterations in carcinogenesis, procainamide may be a useful drug in the prevention of c
89 s studied after the administration of either procainamide (n = 3) or quinidine (n = 3).
90 e-blinded comparative studies or intravenous procainamide (n=53) in a concurrent open-label study.
91                      However, the effects of procainamide on the characteristics of activation waves
92 was to determine the effect of verapamil and procainamide on these manifestations of AF-induced elect
93               The effects of propafenone and procainamide on these parameters, and their antiarrhythm
94 5) phenytoin or propranolol or verapamil; 6) procainamide or hypothermia; and 7) combined procainamid
95 ition of procainamide-hydroxylamine, but not procainamide or its further oxidation products during an
96  T cell clones was used to determine whether procainamide or one of its metabolites could prevent dev
97 e length and refractory periods prolonged on procainamide or quinidine, but no tachyarrhythmias could
98                                    Ajmaline, procainamide, or flecainide administration resulted in S
99 kers (SCB) with either ajmaline, flecainide, procainamide, or pilsicainide to unmask the ECG of Bruga
100                                              Procainamide (PA) at 10 microgram/mL decreased the numbe
101 ents compared with 90% and 80% of saline and procainamide patients (P<.01 versus verapamil).
102           This study compared the effects of procainamide (Pca) and hydralazine (Hyd) with those of s
103 amide (2-AB), 2-aminobenzoic acid (2-AA), or procainamide (proA).
104 n with mass spectrometry (HILIC-UHPLC-MS) of procainamide (PROC) labeled N-glycans were the analytica
105                      Ibutilide shortened and procainamide prolonged action potential diastolic interv
106 on of Dnmt catalytic activity with RG108 and procainamide protected cultured neurons from excessive D
107    The use of prophylactic beta-blockers and procainamide reduces the incidence of AF whereas digoxin
108 droxylamine (PAHA), a reactive metabolite of procainamide, resulted in prompt production of IgM antid
109 ide such that their effects are enhanced and procainamide's effects are diminished.
110                                              Procainamide's prolongation of action potential duration
111                                              Procainamide's prolongation of action potential duration
112                                This includes procainamide-sensitive, adenosine-resistant accessory pa
113                                 By doing so, procainamide significantly decreased the processivity of
114                                              Procainamide slowed mean CT by 40% during S2-S5 pacing,
115                          We report here that procainamide specifically inhibits the hemimethylase act
116    Adenosine and isoproterenol interact with procainamide such that their effects are enhanced and pr
117   Ibutilide increased MAPD/CL ratio, whereas procainamide tended to decrease this ratio (13% versus -
118 ive conduction disease, a low sensitivity to procainamide testing, and a relatively good prognosis in
119 nel blockers such as flecainide, ajmaline or procainamide, thus identifying patients at risk.
120 duced by injecting male and female mice with procainamide-treated T cell clones.
121                At micromolar concentrations, procainamide was found to be a partial competitive inhib
122                                              Procainamide was not a potent inhibitor of the de novo m
123 shes the superior efficacy of ibutilide over procainamide when administered to patients to convert ei
124 mptomatic ventricular arrhythmias related to procainamide, which resolved upon discontinuation of the
125     We also showcase gram-scale synthesis of procainamide with 90% isolated yield.
126 s at baseline and >380 ms in the presence of procainamide would have been required to avoid VF.

 
Page Top